Guidelines Establish the Role of Molecular Testing in Treatment of Patients With CRCApril 18th 2017
Molecular testing of patients with colorectal cancer should be incorporated into standard practice to establish the mutations each patient has that would affect their response to treatment with EGFR-targeted therapies.
V212 Lowers Incidence of Herpes Zoster Infections After TransplantApril 18th 2017
V212, a new inactivated varicella zoster virus vaccine, lowered the cumulative incidence rate of herpes zoster (HZ) infections and HZ-related complications for patients undergoing autologous stem cell transplantation.
Intriguing Biomarker Results in Study of Avelumab in Merkel Cell CarcinomaApril 18th 2017
Responses to treatment with avelumab monotherapy can increase in certain subtypes of patients with metastatic Merkel cell carcinoma, per an analysis of the phase II JAVELIN Merkel 200 trial that was presented during the ASCO-SITC Clinical Immuno-Oncology Symposium.
Searching for the Key to Immunotherapy Response in Head and Neck CancerApril 18th 2017
Immunotherapy agents have shown great promise for the treatment of patients with head and neck cancer; however, only a small subset of patients reap these benefits. Thus, the question becomes: which patients are more likely to benefit from these therapies, and why?
New Conditioning Regimens May Prevent Blood Cancer RelapsesApril 14th 2017
Patients with hematologic malignancies who receive a hematopoietic stem cell transplant (HSCT) still risk treatment failure through relapse. As part of a conditioning regimen prior to allogenic HSCT, strategies are emerging to improve HSCT outcomes by reducing the risk of relapse. Several of these conditioning regimens were reviewed during a satellite symposium to the 2017 BMT Tandem Meetings.